Abstracts submitted to ASCO 2022 and EADO 2022
For our EMRseq project an ASCO Abstract has been successfully submitted. EMRseq is a Registry based outcome analysis on 1,000 patients with BRAF V600 mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition. In BRAF mutated metastatic melanoma, potential outcome differences for different first line choices of treatments including immunotherapy or BRAF-/MEK inhibition are not completely understood. We therefore analyzed the treatment patterns and outcome of systemic therapies for patients with BRAF mutated metastatic melanoma. A group consisting of 20 co-authors has collaborated on this important project. A big thanks to everyone involved in this great project work!
A second abstract has been submitted to EADO 2022 on "Access to standard of care treatment for metastatic melanoma in Europe: first result from the EADO-EUMelaReg 2022 survey". In recent studies that analysed data from years 2015 and 2017 it was found that a large percentage of patients have restricted access to the standard of care systemic treatment for metastatic melanoma. The new survey aims to compare data on current treatment situations among Europe. The results are still unsatisfactory.